The knowns and the unknowns in HER2 testing in breast cancer

American Journal of Clinical Pathology

Volumn 136, Issue 1, 2011, Pages 5-6

  Gown, Allen M ^a   Goldstein, Lynn C ^a  

^a PHENOPATH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; RECEPTOR, ERBB-2;

EID: 79960150758     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP53KBPMDRTYDK     Document Type: Editorial

References (11)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
3. Manion E, Hornick JL, Lester SC, et al. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol. 2011;135:845-851.
4. Ricardo S, Milanezi F, Carvalho S, et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 2007;60:1001-1005. (Pubitemid 47441932)
5. Nunes CB, Rocha RM, Reis-Filho JS, et al. Comparative analysis of six different antibodies against HER2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol. 2008;61:934-938.
6. Nassar A, Cohen C, Siddiqui M. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagn Cytopathol. 2009;37:865-870.
7. Wludarski SC, Bacchi CE. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:466-470.
8. Gown AM, Goldstein LC, Barry TS, et al. Choice of primary anti-HER2 antibody affects concordance of immunohistochemistry (IHC) results with fluorescence in situ hybridization (FISH) for determination of breast cancer HER2 status [abstract]. Mod Pathol. 2008;21:33A-34A.
9. Lehrer J. Annals of science: the truth wears off. New Yorker. December 13, 2010.
10. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977. (Pubitemid 38544278)
11. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271-1277.